Abstract
Antiplatelet therapy following percutaneous coronary intervention (PCI) has evolved along with the development of antiplatelet agents and coronary stents. The use of P2Y12 inhibitor monotherapy is gradually replacing aspirin monotherapy after PCI, as supported by emerging evidence. Aspirin-free P2Y12 inhibitor monotherapy has also been investigated in several prospective studies as a novel antiplatelet therapy for patients undergoing PCI. This brief review highlights the current status of P2Y12 inhibitor monotherapy and offers future perspectives on its use after PCI.
